SS-31 (Elamipretide) and Cardiolipin-Targeted Mitochondrial Research
SS-31, also designated elamipretide, is notable for having an unusually well-defined molecular target — a specific membrane lipid rather than a receptor.
Structure and localisation
SS-31 is a four-residue peptide incorporating a D-amino acid and the unnatural residue dimethyltyrosine. Its alternating aromatic-cationic structure allows it to cross membranes and concentrate in the inner mitochondrial membrane. Crucially, this localisation has been reported to be largely independent of mitochondrial membrane potential, distinguishing it from many cationic compounds that accumulate only in polarised, functioning mitochondria — an important property when studying dysfunctional ones.
Cardiolipin as the target
The peptide associates with cardiolipin1, a distinctive four-tailed phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin is structurally important: it stabilises respiratory chain complexes, supports their organisation into supercomplexes, and maintains the highly folded cristae architecture where oxidative phosphorylation occurs. Cardiolipin abnormalities are a recognised feature of several mitochondrial disorders, including the genetic condition Barth syndrome, in which cardiolipin remodelling is impaired.
Reported effects in research models
Published preclinical work has examined effects on cristae structure, electron transport chain efficiency, and mitochondrial reactive oxygen species production in models of mitochondrial dysfunction. The proposed mechanism is that stabilising cardiolipin interactions improves the structural organisation on which efficient electron transport depends, rather than acting as a conventional antioxidant.
Clinical investigation and its limits
Elamipretide has been evaluated in human clinical trials for primary mitochondrial myopathy and Barth syndrome2. Results across the programme have been mixed, with some trials not meeting primary endpoints — an outcome worth stating plainly, because it illustrates the distance between a well-defined molecular mechanism and demonstrated clinical benefit.
Why it remains a useful research tool
Regardless of clinical outcomes, a compound that localises to a specific inner-membrane lipid gives researchers a way to probe cardiolipin-dependent processes experimentally. That specificity is the source of its ongoing use in mitochondrial biology.
References
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029–2050. doi:10.1111/bph.12461
- Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial of elamipretide in Barth syndrome (TAZPOWER). Genet Med. 2021;23(3):471–478. doi:10.1038/s41436-020-01006-8
Disclosure. This article is educational and summarises published scientific literature. It is not medical advice, and it does not describe outcomes you should expect. These statements have not been evaluated by the Food and Drug Administration, and the products discussed are not intended to diagnose, treat, cure, or prevent any disease. The products discussed are supplied for laboratory and research use only and are not for human or veterinary use, administration, or consumption. For adults 21 and over.
